Iome Bio SA
Have updates for this profile? Please contribute data
= Subscriber Access Only
You are viewing a preview of this profile. Request a Preqin Pro demo for full access to all profiles and underlying data.
With Preqin Pro, you gain an unobstructed view of all alternative asset class activity across institutional investors, fund managers, funds, portfolio companies, deals, exits, and service providers.
Iome Bio SA - overview
Established
2020
Location
Strasbourg, -, France
Primary Industry
Biotechnology
About
Based in France, and founded in 2020 by Arlene Sharpe, Dennis Kasper, and Gordon Freeman, Iome Bio SA develops microbiome-based mechanisms to develop drugs for immuno-oncology. Iome Bio SA raised venture funding from Seventure. As of 2024, the company is led by its CEO, Éric Rambeaux. The company specializes in addressing the challenges of resistance to checkpoint inhibitors, particularly PD-1 blockade.
The firm’s core approach lies in an understanding of the intricate mechanisms underlying immune response and tumor evasion. Iome Bio is developing immuno-oncology targets and antibodies by leveraging access to intellectual property and ongoing sponsored research.
Current Investors
Seventure Partners
Primary Industry
Biotechnology
Sub Industries
Biopharmaceuticals
Website
www.iome-bio.com/
Company Stage
Early Stage
Total Amount Raised
Subscriber access only
Time to go Pro
Get Preqin Pro for unrestricted access to 600,000+ detailed profiles on fund managers, investors, funds, companies, and other alternative asset players. Unlock exclusive data on future plans, company financials, fundraising history, track records, and more.